<DOC>
	<DOCNO>NCT01819779</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic characteristic valsartan S-amlodipine single oral administration Exforge tab . 10/160mg , combination formulation valsartan amlodipine reference drug Lodivixx tab . 5/160mg , combination formulation valsartan S-amlodipine test drug healthy male adult . Additionally safety tolerability two drug evaluate .</brief_summary>
	<brief_title>Clinical Trial Assess Pharmacokinetic Characteristics Lodivixx Tab . 5/160mg Healthy Male Subjects ( N=60 )</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Years 2045 Body weight ≥ 50kg 18 ≤ BMI ≤ 29kg/m2 volunteer Subject serious active cardiovascular , respiratory , hepatologic , renal , hematologic , gastrointestinal , immunologic , dermal , neurologic , psychological disease history disease Subject symptoms acute disease within 28days prior study medication dose Subject know history affect absorption , distribution , metabolism excretion drug Subject clinically significant active chronic disease Subject follow condition laboratory test i. AST ( sGOT ) ALT ( sGPT ) &gt; Upper normal limit × 1.5 ii . Total bilirubin &gt; Upper normal limit × 1.5 iii . renal failure Creatinine clearance &lt; 50mL/min Clinically significant hypotension screen period ( SBP &lt; 100mmHg , DBP &lt; 60mmHg ) Positive test result HBs Ab , HCV Ab , Syphilis regain test Use prescription medication within 14 day prior study medication dosing Use medication overthecounter medication include oriental medication within 7 day prior study medication dose Subject clinically significant allergic disease ( except mild allergic rhinitis mild allergic dermatitis need administer drug ) Subject know hypersensitivity reaction Samlodipine , amlodipine valsartan dihydropyridine derivative Subject able take institutional standard meal Subjects whole blood donation within 60days , component blood donation within 20days Subjects receive blood transfusion within 30days prior study medication dose Participation clinical investigation within 60days prior study medication dose Continued excessive use caffeine ( caffeine &gt; five cups/day ) , alcohol ( alcohol &gt; 30g/day ) severe heavy smoker ( cigarette &gt; 10 cigarette per day ) Subject take meal affect absorption , distribution , metabolism , excretion drug , especially grapefruit juice Subject take inducer inhibitor drug metabolism enzyme barbital within 28days prior study medication dose Continued serum potassium concentration abnormal status ( baseline visit , &lt; 3.5mEq/L &gt; 5.5mEq/L ) Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator Severe renal insufficient subject ( creatinine clearance : le 10mL/min ) Severe hepatic insufficient subject , billiary cirrhosis , biliary obstruction cholestasis patient Combination aliskiren Diabetic patient moderate severe renal insufficient subject ( glomerular filtration rate &lt; 60mL/min/1.73m2 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>